Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease

Scand J Gastroenterol. 1992 Apr;27(4):333-6. doi: 10.3109/00365529209000083.

Abstract

The absorption of bismuth from five 205Bi-labelled pharmaceutically used bismuth compounds was studied in man. From single oral doses of all compounds under investigation only less than 0.1% bismuth was absorbed and excreted with the urine. A significantly higher absorption was observed from the colloidal bismuth subcitrate (0.042% of the dose) and the basic bismuth gallate (0.038%) than from the basic bismuth salicylate, nitrate, and aluminate (0.005-0.002%). No retention of bismuth in the whole body was found from the single dose experiment. The biologic fast-term half-lives of absorbed bismuth were calculated to be 0.12 and 1.5 days.

MeSH terms

  • Adult
  • Aluminum / pharmacokinetics
  • Anti-Ulcer Agents / therapeutic use*
  • Biological Availability
  • Bismuth / pharmacokinetics*
  • Bismuth / therapeutic use
  • Female
  • Gallic Acid / analogs & derivatives
  • Gallic Acid / pharmacokinetics
  • Humans
  • Intestinal Absorption / physiology
  • Male
  • Middle Aged
  • Nitrates / pharmacokinetics
  • Organometallic Compounds / pharmacokinetics
  • Peptic Ulcer / drug therapy*
  • Radioisotopes

Substances

  • Anti-Ulcer Agents
  • Nitrates
  • Organometallic Compounds
  • Radioisotopes
  • bismuth nitrate
  • Gallic Acid
  • Aluminum
  • bismuth tripotassium dicitrate
  • bismuth aluminate
  • Bismuth
  • bismuth subgallate